Table 4 Modeled clinical outcomes of life-time in lamivudine resistant CHB patient with rescue therapies
HBeAg status | Positive | Negative | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Treatment | No | ADV | ADV and LAM | ENT | TNV | No | ADV | ADV and LAM | ENT | TNV |
Cumulative incidence of compensated cirrhosis§ | 0.51 | 0.49 | 0.39 | 0.47 | 0.31 | 0.80 | 0.76 | 0.59 | 0.76 | 0.53 |
Cumulative incidence of decompensated cirrhosis§ | 0.20 | 0.19 | 0.14 | 0.18 | 0.12 | 0.33 | 0.30 | 0.22 | 0.31 | 0.21 |
Cumulative incidence of HCC§ | 0.19 | 0.18 | 0.15 | 0.18 | 0.13 | 0.25 | 0.23 | 0.18 | 0.23 | 0.17 |
Cumulative mortality§# | 0.41 | 0.38 | 0.30 | 0.37 | 0.25 | 0.64 | 0.58 | 0.42 | 0.59 | 0.41 |
Expected life-years | 24.00 | 24.48 | 25.61 | 24.64 | 25.88 | 20.62 | 21.83 | 24.14 | 21.65 | 23.69 |
QALYs | 8.77 | 9.25 | 10.58 | 9.43 | 11.17 | 7.76 | 8.64 | 10.48 | 8.51 | 10.36 |
Total cost ($) | 9478.0 | 13011.9 | 21284.9 | 25387.0 | 27556.3 | 13097.2 | 16229.5 | 25552.8 | 27556.3 | 32270.9 |
Incremental cost ($)& | - | 3533.8 | 11806.9 | 15908.9 | 22452.4 | - | 3132.3 | 12455.6 | 14459.2 | 19173.8 |
Incremental QALYs& | - | 0.47 | 1.81 | 0.66 | 2.40 | - | 0.88 | 2.72 | 0.75 | 2.60 |
ICER† | - | 7468.0 | 6531.7 | 24268.9 | 9359.8 | - | 3552.6 | 4571.7 | 19157.1 | 7370.4 |